Zacks Research Issues Negative Forecast for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Analysts at Zacks Research decreased their Q2 2026 earnings estimates for Teva Pharmaceutical Industries in a research note issued on Monday, April 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.60 for the quarter, down from their prior forecast of $0.62. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q3 2026 earnings at $0.78 EPS, Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.56 EPS, Q1 2027 earnings at $0.60 EPS and FY2027 earnings at $2.77 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%.

Several other research analysts have also recently weighed in on the stock. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Finally, Bank of America decreased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.60 during trading hours on Thursday, hitting $16.22. The company had a trading volume of 11,919,719 shares, compared to its average volume of 9,977,348. The business has a fifty day moving average of $15.11 and a 200-day moving average of $17.49. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a market cap of $18.39 billion, a price-to-earnings ratio of -11.19, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TEVA. Diversify Advisory Services LLC lifted its position in shares of Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after buying an additional 496 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after acquiring an additional 699 shares during the last quarter. Bfsg LLC boosted its stake in shares of Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after purchasing an additional 790 shares in the last quarter. Townsquare Capital LLC grew its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares during the last quarter. Finally, Metis Global Partners LLC increased its position in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after purchasing an additional 860 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.